UBE2S and metastatic malignant neoplasm in the lymph nodes: Lymph node metastasis (95% CI: 1.458–3.095, HR: 2.124, p < 0.001), hematogenous metastasis (95% CI: 1.237–3.367, HR: 2.041, p = 0.005), high UBE2S (95% CI: 1.126–2.625, HR: 1.719, p = 0.012), and FOXM1 (95% CI: 1.181–2.594, HR: 1.750, p = 0.005) expression were also discovered to be risk factors impacting PFS.